171 related articles for article (PubMed ID: 20881376)
1. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease.
He ZY; Ou LM; Zhang JQ; Bai J; Liu GN; Li MH; Deng JM; MacNee W; Zhong XN
Respiration; 2010; 80(6):445-52. PubMed ID: 20881376
[TBL] [Abstract][Full Text] [Related]
2. Effect of low-dose theophylline on airway inflammation in COPD.
Kobayashi M; Nasuhara Y; Betsuyaku T; Shibuya E; Tanino Y; Tanino M; Takamura K; Nagai K; Hosokawa T; Nishimura M
Respirology; 2004 Jun; 9(2):249-54. PubMed ID: 15182277
[TBL] [Abstract][Full Text] [Related]
3. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations.
Seemungal TA; Wilkinson TM; Hurst JR; Perera WR; Sapsford RJ; Wedzicha JA
Am J Respir Crit Care Med; 2008 Dec; 178(11):1139-47. PubMed ID: 18723437
[TBL] [Abstract][Full Text] [Related]
4. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease.
Gamble E; Grootendorst DC; Brightling CE; Troy S; Qiu Y; Zhu J; Parker D; Matin D; Majumdar S; Vignola AM; Kroegel C; Morell F; Hansel TT; Rennard SI; Compton C; Amit O; Tat T; Edelson J; Pavord ID; Rabe KF; Barnes NC; Jeffery PK
Am J Respir Crit Care Med; 2003 Oct; 168(8):976-82. PubMed ID: 12816740
[TBL] [Abstract][Full Text] [Related]
5. The effect of clarithromycin on inflammatory markers in chronic obstructive pulmonary disease: preliminary data.
Basyigit I; Yildiz F; Ozkara SK; Yildirim E; Boyaci H; Ilgazli A
Ann Pharmacother; 2004 Sep; 38(9):1400-5. PubMed ID: 15252191
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease.
Sethi S; Wrona C; Eschberger K; Lobbins P; Cai X; Murphy TF
Am J Respir Crit Care Med; 2008 Mar; 177(5):491-7. PubMed ID: 18079493
[TBL] [Abstract][Full Text] [Related]
7. Changes in sputum T-lymphocyte subpopulations at the onset of severe exacerbations of chronic obstructive pulmonary disease.
Tsoumakidou M; Tzanakis N; Chrysofakis G; Kyriakou D; Siafakas NM
Respir Med; 2005 May; 99(5):572-9. PubMed ID: 15823454
[TBL] [Abstract][Full Text] [Related]
8. Exacerbations of chronic obstructive pulmonary disease.
Wedzicha JA; Donaldson GC
Respir Care; 2003 Dec; 48(12):1204-13; discussion 1213-5. PubMed ID: 14651761
[TBL] [Abstract][Full Text] [Related]
9. Modulation of neutrophil and inflammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatment.
Parnham MJ; Culić O; Eraković V; Munić V; Popović-Grle S; Barisić K; Bosnar M; Brajsa K; Cepelak I; Cuzić S; Glojnarić I; Manojlović Z; Novak-Mircetić R; Oresković K; Pavicić-Beljak V; Radosević S; Sucić M
Eur J Pharmacol; 2005 Jul; 517(1-2):132-43. PubMed ID: 15964564
[TBL] [Abstract][Full Text] [Related]
10. Antibiotic resistance in sputum isolates of Streptococcus pneumoniae in chronic obstructive pulmonary disease is related to antibiotic exposure.
Desai H; Richter S; Doern G; Heilmann K; Dohrn C; Johnson A; Brauer A; Murphy T; Sethi S
COPD; 2010 Oct; 7(5):337-44. PubMed ID: 20854048
[TBL] [Abstract][Full Text] [Related]
11. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease.
Brightling CE; McKenna S; Hargadon B; Birring S; Green R; Siva R; Berry M; Parker D; Monteiro W; Pavord ID; Bradding P
Thorax; 2005 Mar; 60(3):193-8. PubMed ID: 15741434
[TBL] [Abstract][Full Text] [Related]
12. MMP-9, TIMP-1 and inflammatory cells in sputum from COPD patients during exacerbation.
Mercer PF; Shute JK; Bhowmik A; Donaldson GC; Wedzicha JA; Warner JA
Respir Res; 2005 Dec; 6(1):151. PubMed ID: 16372907
[TBL] [Abstract][Full Text] [Related]
13. Bronchodilator reversibility, airway eosinophilia and anti-inflammatory effects of inhaled fluticasone in COPD are not related.
Reid DW; Wen Y; Johns DP; Williams TJ; Ward C; Walters EH
Respirology; 2008 Nov; 13(6):799-809. PubMed ID: 18811878
[TBL] [Abstract][Full Text] [Related]
14. [Exacerbations of chronic obstructive pulmonary disease and the role of sputum bacteriological examination].
Noweta K; Frankowska M; Grzelewska-Rzymowska I
Pneumonol Alergol Pol; 2006; 74(4):396-402. PubMed ID: 17427149
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment with macrolides - light in the darkness of COPD therapy?
Duranti R
Respiration; 2010; 80(6):441-2. PubMed ID: 21079411
[No Abstract] [Full Text] [Related]
16. Use of long-term macrolide therapy in chronic obstructive pulmonary disease.
Ramos FL; Criner GJ
Curr Opin Pulm Med; 2014 Mar; 20(2):153-8. PubMed ID: 24378875
[TBL] [Abstract][Full Text] [Related]
17. [Expression and significance of beta(2)-adrenoreceptor in inflammatory cells of patients with chronic obstructive pulmonary disease].
Zhu WJ; He B; Xu M
Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(30):2099-102. PubMed ID: 19080468
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of budesonide on inflammatory status in COPD.
Boorsma M; Lutter R; van de Pol MA; Out TA; Jansen HM; Jonkers RE
COPD; 2008 Apr; 5(2):97-104. PubMed ID: 18415808
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory response in acute viral exacerbations of COPD.
Rohde G; Borg I; Wiethege A; Kauth M; Jerzinowski S; An Duong Dinh T; Bauer TT; Bufe A; Schultze-Werninghaus G
Infection; 2008 Oct; 36(5):427-33. PubMed ID: 18795228
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of anti-inflammatory treatment with benacort in exacerbations of chronic obstructive lung disease].
Kolesnikov VV; Korol'chuk IS
Ter Arkh; 2003; 75(1):55-8. PubMed ID: 12652959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
